Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTL NASDAQ:BDRX NASDAQ:ENVB NASDAQ:HEPA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$5.25-1.1%$11.32$4.20▼$28.60$3.68M1.46277,142 shs72,067 shsBDRXBiodexa Pharmaceuticals$6.04+0.3%$7.21$5.00▼$108.90$3.75M0.87168,524 shs39,304 shsENVBEnveric Biosciences$0.94-3.1%$1.19$0.85▼$8.33$3.06M0.581.13 million shs55,809 shsHEPAHepion Pharmaceuticals$0.06-0.9%$0.06$0.03▼$0.08$629K1.5270,538 shs5,606 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences0.00%+17.74%-47.01%-17.42%-25.00%BDRXBiodexa Pharmaceuticals0.00%+6.55%-14.49%-42.12%+601,999,900.00%ENVBEnveric Biosciences0.00%+6.58%-11.83%-23.63%-87.09%HEPAHepion Pharmaceuticals0.00%-28.85%-11.90%-28.20%-99.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$5.25-1.1%$11.32$4.20▼$28.60$3.68M1.46277,142 shs72,067 shsBDRXBiodexa Pharmaceuticals$6.04+0.3%$7.21$5.00▼$108.90$3.75M0.87168,524 shs39,304 shsENVBEnveric Biosciences$0.94-3.1%$1.19$0.85▼$8.33$3.06M0.581.13 million shs55,809 shsHEPAHepion Pharmaceuticals$0.06-0.9%$0.06$0.03▼$0.08$629K1.5270,538 shs5,606 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences0.00%+17.74%-47.01%-17.42%-25.00%BDRXBiodexa Pharmaceuticals0.00%+6.55%-14.49%-42.12%+601,999,900.00%ENVBEnveric Biosciences0.00%+6.58%-11.83%-23.63%-87.09%HEPAHepion Pharmaceuticals0.00%-28.85%-11.90%-28.20%-99.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.00Buy$24.00357.14% UpsideBDRXBiodexa Pharmaceuticals 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00963.49% UpsideHEPAHepion Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HEPA, BDRX, ARTL, and ENVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/8/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold8/26/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/18/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/4/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $18.007/8/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/8/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$20.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$5.31 per shareN/ABDRXBiodexa Pharmaceuticals$470K7.97N/AN/A$2.91 per share2.08ENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.83M-$19.05N/AN/AN/AN/A-497.68%-213.76%11/10/2025 (Estimated)BDRXBiodexa Pharmaceuticals-$7.32MN/A0.00N/AN/AN/AN/AN/AN/AENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-341.48%-240.71%11/12/2025 (Estimated)HEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%11/12/2025 (Estimated)Latest HEPA, BDRX, ARTL, and ENVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ENVBEnveric Biosciences-$5.25-$0.97+$4.28-$0.97N/AN/A8/13/2025Q2 2025ARTLArtelo Biosciences-$0.13-$5.61-$5.48-$5.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/ABDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A0.390.39BDRXBiodexa Pharmaceuticals0.011.751.75ENVBEnveric BiosciencesN/A2.422.42HEPAHepion PharmaceuticalsN/A1.301.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%BDRXBiodexa Pharmaceuticals17.51%ENVBEnveric Biosciences13.82%HEPAHepion Pharmaceuticals17.24%Insider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences5.80%BDRXBiodexa Pharmaceuticals0.34%ENVBEnveric Biosciences3.20%HEPAHepion Pharmaceuticals0.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences5700,000663,000Not OptionableBDRXBiodexa Pharmaceuticals20620,000618,000Not OptionableENVBEnveric Biosciences203.25 million3.14 millionNot OptionableHEPAHepion Pharmaceuticals2011.44 million6.63 millionNo DataHEPA, BDRX, ARTL, and ENVB HeadlinesRecent News About These CompaniesHepion Pharmaceuticals CFO John Brancaccio resigns effective MondayJuly 1, 2025 | investing.comHepion Pharmaceuticals Successfully Completes Application to the OTCQBJune 25, 2025 | globenewswire.comHEPA Hepion Pharmaceuticals, Inc.CJune 22, 2025 | seekingalpha.comHepion names new interim CEO, shifts to diagnostic innovationJune 18, 2025 | njbiz.comNHepion Pharmaceuticals Appoints Kaouthar Lbiati As Interim CEOJune 17, 2025 | nasdaq.comHepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive OfficerJune 16, 2025 | manilatimes.netMHepion Pharmaceuticals reports annual meeting resultsJune 14, 2025 | investing.comHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 13, 2025 | finanznachrichten.deHepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'May 12, 2025 | msn.comHepion Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 12, 2025 | globenewswire.comHepion Pharmaceuticals Enters Binding LOI with New Day Diagnostics for In-Licensing of CE-Marked Diagnostic TestsMay 9, 2025 | nasdaq.comHepion Partners With New Day Diagnostics To Commercialize Diagnostic TestsMay 9, 2025 | nasdaq.comHepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCCMay 7, 2025 | globenewswire.comHepion Pharmaceuticals faces potential Nasdaq delistingMarch 22, 2025 | investing.comHepion Pharmaceuticals enacts reverse stock splitMarch 21, 2025 | investing.comHepion Pharmaceuticals trading halted, news pendingMarch 18, 2025 | markets.businessinsider.comHepion Pharmaceuticals announces 1-for-50 reverse stock splitMarch 14, 2025 | markets.businessinsider.comHepion Pharmaceuticals Announces Reverse Stock SplitMarch 14, 2025 | globenewswire.comHepion Pharmaceuticals Inc’s Stock Drama: Could This Be a Game-Changer for HEPA Investors?February 4, 2025 | bovnews.comBHepion Pharmaceuticals Inc (HEPA) Stock: More Resilient Than It AppearsJanuary 28, 2025 | bovnews.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHEPA, BDRX, ARTL, and ENVB Company DescriptionsArtelo Biosciences NASDAQ:ARTL$5.25 -0.06 (-1.13%) Closing price 04:00 PM EasternExtended Trading$5.49 +0.24 (+4.65%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Biodexa Pharmaceuticals NASDAQ:BDRX$6.04 +0.02 (+0.33%) Closing price 03:57 PM EasternExtended Trading$6.18 +0.14 (+2.32%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Enveric Biosciences NASDAQ:ENVB$0.94 -0.03 (-3.05%) Closing price 04:00 PM EasternExtended Trading$0.96 +0.02 (+2.41%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Hepion Pharmaceuticals NASDAQ:HEPA$0.06 0.00 (-0.90%) As of 01:11 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
